40782-45-4

Usage

InChI:InChI=1/C11H13ClO2/c1-8(2)7-14-10-5-3-9(4-6-10)11(12)13/h3-6,8H,7H2,1-2H3

Upstream product

• 30762-00-6 4-isobutoxybenzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 124403-90-3 methyl 4-(2-methylpropoxy)benzoate 
• 1015423-08-1 ethyl 4-(2-methylpropoxy)benzoate 
• 120-47-8 Ethyl 4-hydroxybenzoate 

Downstream Products

• 110331-93-6 4-isobutoxy-benzoic acid-(1,1-dimethyl-3-piperidino-propyl ester) 
• 110746-54-8 4-isobutoxy-benzoic acid-(3-diethylamino-2,2-dimethyl-propyl ester) 
• 109469-21-8 4-isobutoxy-benzoic acid-(3-dimethylamino-2,2-dimethyl-propyl ester) 
• 109469-22-9 4-isobutoxy-benzoic acid-(3-dimethylamino-1,1-dimethyl-propyl ester) 
• 139233-28-6 N-Benzothiazol-2-yl-4-isobutoxy-benzamide 
• 1440967-51-0 C₂₉H₃₁N₃O₆S 
• 1373823-20-1 4-(2-methylpropoxy)-N-[8-methyl-3-(pyrrolidin-1-ylmethyl)-quinolin-7-yl]benzamide 
• 91403-79-1 2-(4-Isobutoxy-benzoylamino)-5,5-dimethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid ethyl ester 
• 102456-97-3 4-isobutoxy-benzoic acid-[3-(ethyl-propyl-amino)-1,2-dimethyl-propyl ester] 
• 299-61-6 4-isobutoxy-benzoic acid-(3-diethylamino-1,2-dimethyl-propyl ester) 

Relevant academic research and scientific papers

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.

Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3- aminomethylquinolines: Reducing human ether-a-go-go-related gene (hERG) associated liabilities

Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-{3-[(1R)-1-{[2-(acetylamino)ethyl]amino} ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.